Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

UROGEN PHARMA LTD

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: Public

Established: 2004-01-01

Employees: 201

Market Cap: -

Website: http://www.urogen.com

Clinical Trials

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

Not Applicable

Completed

Conditions: Urologic Neoplasms
Urinary Bladder Neoplasms
Urologic Diseases
Neoplasms
Urinary Bladder Diseases

Interventions: Device: 40 mg MMC in 40 mL TC-3.
Device: 80 mg MMC in 40 mL TC-3.

First Posted Date: 2016-09-07

Last Posted Date: 2016-09-08

Lead Sponsor: UroGen Pharma Ltd.

Target Recruit Count: 18

Registration Number: NCT02891460

Locations: 🇮🇳
Rajiv Gandhi Cancer Institute & Research Center, Delhi, New Delhi, India

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

Phase 3

Completed

Conditions: Carcinoma, Transitional Cell
Transitional Cell Carcinoma of Renal Pelvis

Interventions: Drug: UGN-101 instillations

First Posted Date: 2016-06-08

Last Posted Date: 2020-12-22

Lead Sponsor: UroGen Pharma Ltd.

Target Recruit Count: 71

Registration Number: NCT02793128

Locations: 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸
Loma Linda Cancer Center, Loma Linda, California, United States
🇺🇸
University of California, Los Angeles, California, United States

and more 21 locations

Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")

Phase 1

Withdrawn

Conditions: Overactive Bladder

Interventions: Drug: 300 IU of BotuGelTM (60ml)
Drug: 400 IU of BotuGelTM (60ml)
Device: TC-3 Gel

First Posted Date: 2016-02-04

Last Posted Date: 2017-06-16

Lead Sponsor: UroGen Pharma Ltd.

Registration Number: NCT02674269

Locations: 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇱
Meir Medical Center, Kfar Saba, Israel

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Phase 2

Completed

Conditions: Bladder Cancer
Neoplasms
Urologic Diseases
Urinary Bladder Diseases

Interventions: Drug: 120 mg MMC in 90ml gel
Drug: 140 mg MMC in 90ml gel
Drug: 140 mg MMC in 60ml gel
Drug: 160 mg MMC in 90ml gel
Drug: 160 mg MMC in 60ml gel
Drug: 120 mg MMC in 60ml gel

First Posted Date: 2014-12-04

Last Posted Date: 2017-06-16

Lead Sponsor: UroGen Pharma Ltd.

Target Recruit Count: 14

Registration Number: NCT02307487

Locations: 🇮🇱
Wolfson Medical Center of Holon, Department of Urology, Holon, Israel
🇮🇱
Meir Medical Center, Kfar Saba, Israel

Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients

Phase 1

Terminated

Conditions: Overactive Bladder

Interventions: Device: BTX mixed with TC-3 Gel

First Posted Date: 2014-07-01

Last Posted Date: 2016-03-01

Lead Sponsor: UroGen Pharma Ltd.

Target Recruit Count: 3

Registration Number: NCT02179099

Locations: 🇮🇱
Urology Department, Edith Wolfson Medical Center, Holon, Israel

Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients

Phase 1

Completed

Conditions: Interstitial Cystitis
IC

Interventions: Device: TC-3 Gel mixed with Botox (BTX)

First Posted Date: 2013-11-28

Last Posted Date: 2016-04-12

Lead Sponsor: UroGen Pharma Ltd.

Target Recruit Count: 15

Registration Number: NCT01997983

Locations: 🇮🇱
Assaf Harofeh Medical Center, Zerifin, Israel

Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC

Not Applicable

Completed

Conditions: Carcinoma of Urinary Bladder, Superficial

Interventions: Device: 40 mg MMC gel
Other: Standard of care MMC mixed with water
Device: 80 mg MMC gel

First Posted Date: 2013-03-04

Last Posted Date: 2017-06-16

Lead Sponsor: UroGen Pharma Ltd.

Target Recruit Count: 80

Registration Number: NCT01803295

Locations: 🇮🇱
Carmel Medical Center of Haifa, Department of Urology, Haifa, Israel
🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇱
Wolfson Medical Center of Holon, Department of Urology, Holon, Israel

and more 10 locations

A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)

Not Applicable

Withdrawn

Conditions: Non Muscle Invasive Bladder Cancer

Interventions: Device: TC-3 hydrogel

First Posted Date: 2013-02-26

Last Posted Date: 2015-09-01

Lead Sponsor: UroGen Pharma Ltd.

Registration Number: NCT01799499

Locations: 🇮🇱
Western Galilee Hospital Nahariya, Nahariya, Israel

Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer

Not Applicable

Completed

Conditions: Carcinoma of Urinary Bladder, Invasive

Interventions: Device: TC-3 gel
Device: TC-3 gel mixed with Mitomycin C (MMC)

First Posted Date: 2012-07-24

Last Posted Date: 2013-05-07

Lead Sponsor: UroGen Pharma Ltd.

Target Recruit Count: 7

Registration Number: NCT01648010

Locations: 🇮🇱
Barzilai Hospital, Ashkelon, Israel
🇮🇱
Wolfson, Holon, Israel
🇮🇱
Beilinson, Petah-Tikva, Israel

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy